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Notch signaling influences effector
functions in fully differentiated CD4+
T cells. Laky et al. show that Notch can
also enhance T cell activation during the
priming phase by increasing the
frequency of CD4+ T cells that respond
and by improving the quality of the
response on a per-cell basis.
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Adaptive immune responses begin when naive CD4+
T cells engage peptide+major histocompatibility
complex class II and co-stimulatory molecules on
antigen-presenting cells (APCs). Notch signaling
can influence effector functions in differentiated
CD4+ T helper and T regulatory cells. Whether and
how ligand-induced Notch signaling influences the
initial primingofCD4+Tcells hasnotbeenaddressed.
We have found that Delta Like Ligand 4 (DLL4)-
induced Notch signaling potentiates phosphatidyli-
nositol 3-OH kinase (PI3K)-dependent signaling
downstream of the T cell receptor+CD28, allowing
naive CD4+ T cells to respond to lower doses of anti-
gen. In vitro, DLL4-deficient APCs were less efficient
stimulators of CD4+ T cell activation, metabolism,
proliferation, and cytokine secretion. With deletion
of DLL4 from CD11c+ APCs in vivo, these deficits
translated to an impaired ability tomount an effective
CD4+-dependent anti-tumor response. These data
implicate Notch signaling as an important regulator
of adaptive immune responses.
INTRODUCTION
Adaptive immune responses begin when a naive T cell encoun-
ters peptide+major histocompatibility complex (pMHC) on anti-
gen-presenting cells (APCs) via its antigen-specific receptor
(TCR). Any given pMHC combination is displayed at low density
on an APC, making it essential that T cells become activated at
low TCRoccupancy (Lanzavecchia et al., 1999). Onemechanism
that allows naive T cells to become activated in response to
lower doses of antigen (Ag) is co-stimulation (Chen and Flies,
2013). CD28 is the primary co-stimulatory molecule for naive
T cells. Constitutive expression of the CD28 ligand CD80 is
a feature that distinguishes ‘‘professional APCs’’ from other
pMHCII-bearing cells.
Generation of fully differentiated CD4+ T effector cells from
naive T cells takes place over the course of approximately
1.5 days, which can be functionally divided into three phases:
priming, proliferation, and differentiation (Jelley-Gibbs et al.,
2008). The priming phase encompasses the time of initial80 Immunity 42, 80–94, January 20, 2015 ª2015 Elsevier Inc.pMHC:TCR engagement until the first cell division. During prim-
ing, sustained signaling by TCR+CD28 leads to expression of
early activation antigens, secretion of interleukin-2 (IL-2), and
preparation to enter the cell cycle. The later phases of prolifera-
tion and differentiation are characterized by cell division, which is
initially driven by TCR and becomes increasingly Ag indepen-
dent. Cytokine and Notch receptors are major influencers of
gene expression in CD4+ T helper (Th) and T regulatory (Treg)
cells and in CD8+ cytotoxic T cells during the differentiation
phase (Radtke et al., 2013). However, little is known about the
effects of Notch signaling in CD4+ T cells during the first few
hours after Ag encounter.
In the priming phase, CD4+ T cells undergo activation-induced
metabolic changes to meet the demands of proliferation and
effector function (MacIver et al., 2013). The phosphatidylinosi-
tol-3-OH kinase (PI3K) and mammalian target of rapamycin
(mTOR) pathways have emerged as key regulators of T cell prim-
ing. Activation of these pathways downstream of TCR+CD28
increases nutrient uptake and stimulates synthesis of proteins,
lipids, and nucleotides, which are prerequisites for IL-2 secretion
and cell division. A positive correlation between Notch, PI3K,
and mTOR activation in T cell acute lymphoblastic leukemia
cells (T-ALL) (Chan et al., 2007) led us to hypothesize that Notch
signaling might enhance CD4+ T cell priming.
Signaling through mammalian Notch receptors begins with
binding of a Notch receptor to a ligand (NotchL) of the Delta-
like or Jagged family. Ligand binding initiates cleavages that
release the intracellular domain of Notch (NICD) and allow its
nuclear translocation. In the nucleus, NICD, RBPJ, and co-acti-
vators form a transcriptional complex. The promoters of true
‘‘Notch target’’ genes contain binding sites that are directly
bound by NICD+RBPJ, for example Hes1 (Fischer and Gessler,
2007). Many direct target genes are transcription factors that
regulate a second tier of ‘‘Notch-responsive’’ genes, which in
thymocytes include the genes encoding glucose transporter-1
(Glut1) (Slc2a1), CD71 (Tfrc), and CD98 (Slc3a2) (Palomero
et al., 2007; O’Donnell et al., 2006). Notch can also act via
non-canonical pathways, although the mechanisms are less
well understood (Minter and Osborne, 2012).
We have developed model systems in which Notch signaling
was manipulated in wild-type (WT) T cells indirectly, by control-
ling the availability of an activating NotchL on APCs. To assess
the activation requirements of naive T cells necessitates the
use of T cells that have not been previously activated (Inaba
and Steinman, 1984), precluding the use of retrovirally trans-
fected T cells. Our approach circumvented the toxicity and
nonspecific effects of pharmacological Notch inhibitors. More-
over, the use of unmanipulated T cells with endogenous Notch
expression ensured that Notch signaling remained ligand depen-
dent, did not exceed physiological limits, and was sensitive to
positive- and negative-feedback mechanisms. We tested the
ability of DLL4-bearing APCs to drive CD4+ T-cell-dependent im-
mune responses in vivo by using adoptive transfer and tumor
eradication protocols. To dissect the mechanisms underlying
in vivo phenotypes, we devised an in vitro system with an Ag-
presenting cell line so that the source of NotchL, MHC, and
co-stimulatory molecules were defined and amenable to
manipulation. This system allowed us to characterize priming
of a synchronized population of T cells with or without Notch
signaling.
We demonstrate that DLL4 is a physiologically relevant regu-
lator of CD4+ T cell priming in vivo and in vitro. In concert
with TCR+CD28 signaling, DLL4-induced Notch signaling
allowed more T cells to respond at lower doses of Ag, which
increased the magnitude of primary responses. Higher amounts
of nutrient receptor expression and increased biomass indicated
that Notch signaling also improved responses on a per-cell
basis. DLL4-deficient APCs were less potent stimulators of
CD4+ T cell metabolism, proliferation, and cytokine secretion,
particularly when the concentration of Ag was low. The co-
stimulatory effects of DLL4 were predicated on PI3K signaling
downstream of TCR+CD28. In the absence of Ag, CD28 engage-
ment, or PI3K activity, DLL4 had minimal effect on any of the
parameters measured. Thus DLL4:Notch acted as co-stimula-
tors of CD80:CD28-mediated co-stimulation in Ag-specific
CD4+ T cells.
RESULTS
The NotchL DLL4 Is Expressed on APCs
Naive CD4+ T cells uniformly expressed Notch1 protein on their
surface (Figures 1A and 1B). After stimulation Notch1 was upre-
gulated in an Ag dose-dependent manner and Notch2 was
induced. This was also true for mice with a diverse T cell reper-
toire and for all of the TCRab transgenic mice analyzed (data not
shown).
It has been reported that APCs express mRNA coding for
NotchL (Cheng et al., 2010). We examined MHCII+-enriched
splenocytes and found that DLL4 was the only NotchL detected
at the protein level (Figure S1A available online). DLL4+ cells
consistently accounted for2%of total MHCII+ cells (Figure 1C).
Cells within the DLL4+ population were predominantly large,
CD19CD11c+MHCII+CD54+CD80+CD11b+ cells, consistent
with the phenotype of myeloid dendritic cells (DCs). DLL4 was
not uniformly expressed by these APCs (Figures S1A and
S1B); rather, the frequency of DLL4+ DCs varied from 20% to
60% of total CD19CD11c+. The presence of DLL4 on a subset
of DCs was provocative and led us to ask what effect DLL4 had
on CD4+ T cell activation.
DLL4 on DCs Enhances CD4+ T Cell Activation In Vivo
To ascertain whether DLL4 expression on CD11c+ cells was
functionally relevant in vivo, we generated animals in which
DLL4 was conditionally deleted in DCs (Dll4/). Itgax-cre-medi-
ated deletion of DLL4 was efficient and had no effect on T celldevelopment, the frequency of DCs, or the expression of other
NotchL or T cell stimulatory molecules on DCs (Figures S1B–
S1D and data not shown). TCR transgenic Marilyn T cells that
recognize a peptide derived from the male H-Y Ag presented
by MHCII I-Ab were transferred to WT or Dll4/ recipients. After
3 days donor cells were recovered and examined for evidence
of activation (Figure 1D). Marilyn T cells transferred to recipients
that did not express H-Y (WT or Dll4/) remained naive
(FSCloCD98loCD71). When transferred to recipients that
expressed H-Y, Marilyn T cells became activated in both WT
and Dll4/ hosts. However, in Ag-bearing recipients whose
CD11c+ APCs lacked DLL4, Marilyn T cells were smaller (FSC)
and expressed significantly lower amounts of activation markers
such as CD98 and CD71, indicative of suboptimal activation.
These data indicate that DLL4 on CD11c+ DCs improved the
quality of the CD4+ T cell response on a per-cell basis.
NotchL on APCs Enhances T Cell Activation In Vitro
To determine whether DLL4 influenced the frequency of cells
that reached the threshold for activation, we looked at induction
of an early activation marker. Within 24 hr after transfer, CD69
was uniformly high on Marilyn T cells transferred to WT or
Dll4/ Ag-bearing male recipients (data not shown). Such a
rapid and homogenous response indicated that the CD69
response of Marilyn T cells had reached a plateau in response
to the amount of endogenously expressed Ag. To better control
the concentration of Ag, we primed Marilyn T cells in vitro by us-
ing freshly isolated WT or Dll4/ DCs to present Dby peptide.
As was the case in vivo, T cells stimulated by Dll4/ DCs were
smaller than T cells stimulated by WT DCs (Figure 1E). Once
the amount of Ag was titrated down, it became clear that
DLL4 increased the frequency of T cells that became CD69+
(Figure 1F).
An essential helper function performed by activated CD4+
T cells is IL-2 production. To quantify the frequency of cells
secreting IL-2, we used capture assays (Figure 1F). As expected,
IL-2+ cells were a subset of the activated CD69+CD4+ T cell pop-
ulation. Significantly fewer T cells secreted IL-2 when stimulated
with Dll4/ than with WT APCs. Thus DLL4 increased the fre-
quency of cells that became activated and acquired effector
function, as measured by CD69 induction and cytokine secre-
tion, respectively. Taken altogether, the data show that DLL4
expression on DCs enhanced the frequency of CD4+ T cells
that responded and the quality of the response on a per-cell ba-
sis, in vivo and in vitro.
The CD11c+ DC population was heterogeneous in DLL4
expression. To compare the stimulatory capacity of APCs that
differed only in the expression of a NotchL, we sought a cell
line that could substitute for the DLL4+ splenocytes. P13.9 cells
were originally created by engineering L cells to express MHCII,
CD54, and CD80. This APC line has been used to demonstrate
that CD80:CD28 interactions enhance CD69 and IL-2 induction
by CD4+ T cells stimulated by peptide Ag (Naramura et al.,
1998; Itoh and Germain, 1997). TheMHCII+CD80+CD54+ pheno-
type of P13.9 cells matched the phenotype of the DLL4+ APCs
we identified in spleen but lacked endogenous NotchL. We
transfected P13.9 cells with DLL4 or empty vector and estab-
lished stable cell lines with equivalent expression of MHC,
CD54, GFP, and CD80.Immunity 42, 80–94, January 20, 2015 ª2015 Elsevier Inc. 81
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When used to present pigeon cytochrome c (PCC) peptide in
the context of I-Ek to 5cc7 TCR transgenic T cells, DLL4-P13.9
cells were comparable to splenic DCs, and both of these cell
types weremore potent stimulators than control P13.9 cells (Fig-
ure 2A). CD69 induction was Ag dependent; DLL4 alone did not
induce CD69 expression. The frequency of CD69+ T cells was
significantly higher with DLL4-P13.9 than control P13.9 APCs
across a range of Ag doses (Figure 2B). The ability of DLL4 to
reduce the threshold of Ag necessary for a naive CD4+ T cell to
respond is demonstrated in that the frequency of CD69+
T cells reached a plateau by 10 nM PCC in the presence of
DLL4; whereas in its absence, the frequency of CD69+ cells still
increased significantly as PCC was increased from 100 nM to
1,000 nM (p = 0.006).
T cell proliferation, as assessed by 3H uptake and CFSE dilu-
tion, was impaired when APCs lacked DLL4 (Figures 2C and 2E).
This was largely because in the absence of a NotchL, fewer cells
were recruited into the proliferating pool (Figures 2D, 2E, and
S2A). As was the case with Marilyn T cells responding to Dby,
DLL4 increased the frequency of 5cc7 T cells that committed
to proliferation, as measured by increased biomass at day 1
across a range of PCC concentrations (Figure 2D). On day 3,
the frequency of cells that remained undivided decreased by
80% from 4.7% to 0.8% (Figures 2E and S2A), which reflects a
3-fold increase in the frequency of input cells that remained
quiescent in the absence of DLL4.
Notch signaling has been reported to influence T cell survival
(Helbig et al., 2012; Jehn et al., 1999). In the presence of NotchL,
the number of cells recovered after 3 days of culture was signif-
icantly higher when T cells were stimulated with low-, but not
with high-, dose Ag (Figure 2F). The decreased cellularity in
DLL4-P13.9 cultures with high-dose PCC was probably due to
increased activation-induced cell death (Lenardo, 1991),
increased cytokine secretion (Figure S2B), and nutrient deple-
tion. In any case, we saw no evidence that DLL4 provided pro-
tection from cell death.
DLL4 Facilitates T Cell Expansion by Relieving
Metabolic Constraints
Proliferation requires increased nutrient uptake (MacIver et al.,
2013). Because the expression of nutrient transporters is low
on quiescent T cells, naive T cells have a cell-intrinsic limitation
on the amount of nutrients that they can acquire. In thymocytes,
several nutrient transporters are Notch responsive, including
CD71 and Glut1 (Ciofani and Zu´n˜iga-Pflu¨cker, 2005; Kelly
et al., 2007). When mature T cells were primed with low-doseFigure 1. Notch Ligand DLL4 Is Expressed on APCs and Is Functionall
(A) 5cc7 T cells incubated overnight with WT CD11c+ splenocytes, with or witho
(B) 5cc7 T cells incubated overnight with WT CD11c+ splenocytes and increasin
(C) WT splenocytes, enriched for MHCII+ cells and analyzed for expression of D
DLL4+ and DLL4 cells gated and compared for expression of the indicated pro
(D) Top: Marilyn T cells analyzed for signs of activation 3 days after transfer to
(solid lines). Female littermates lacking H-Y (dotted lines) served as negative c
Mean ± SEM, for FSC *p% 0.05, CD98 *p% 0.03, CD71 *p% 0.001.
(E) Marilyn T cells analyzed for FSC after overnight stimulation by WT or Dll4/
*p% 0.05.
(F) Marilyn T cells incubated overnight with WT or Dll4/ CD11c+ splenocytes p
Mean ± SEM fromR3 determinations, CD69 *p% 0.0001, IL-2 *p = 0.0001.
See also Figure S1.peptide, DLL4 increased the frequency of T cells with high
CD71 and Glut1 (Figures 3A). In addition to an increase in the fre-
quency of responders, T cells activated by DLL4+ APCs ex-
pressed more of these transporters on a per-cell basis than
T cells stimulated in the absence of NotchL.
DLL4 increased expression of nutrient receptors on Marilyn
T cells stimulated by DCs in vivo and on 5cc7 T cells stimulated
by DLL4-P13.9 APCs in vitro. In vitro we could quantify the func-
tional impact that the changes in receptor expression had on
nutrient uptake. Fluorescently labeled analogs of transferrin (Tf)
or glucose were added to the media of T cells cultured with
PCC and control or DLL4-P13.9 APCs (Figures 3B and 3C).
Only activated CD69+CD71+ T cells took up Tf. Despite a high
concentration of Tf in the culture media, resting (CD71) cells
did not have the capacity to take in Tf. DLL4 on APCs increased
the frequency of T cells that became activated and able to endo-
cytose Tf. Moreover, the amount of Tf acquired by a cell was
directly correlated with its Tf receptor expression, such that
the mean fluorescence intensity (MFI) of Tf was higher for
T cells primed in the presence of NotchL. Thus on a per-cell ba-
sis, T cells stimulated in the presence of DLL4 were able to ac-
quire more Tf:iron complexes than CD71+ T cells deprived of
Notch signaling. These data are consistent with previous studies
illustrating that CD71 is a rate-limiting factor for Tf transport in
T cells (Bayer et al., 1998; Brekelmans et al., 1994a). DLL4+
APCs also induced more T cells to increase Glut1 expression
and glucose consumption, although the increase in MFI of
glucose taken up on a per-cell basis between control and
DLL4 cultures did not reach statistical significance. Neverthe-
less, the data support the hypothesis that one mechanism by
which DLL4-induced Notch signaling facilitates T cell activation
and expansion is to relieve cell-intrinsic metabolic constraints
that are imposed by the paucity of nutrient transporters on naive
T cells.
Rbpj/ T cells can bind to NotchL and undergo cleavage of
Notch receptors but cannot modify transcription of target genes.
The frequency of activated, blasting Rbpj/ T cells was the
same regardless of whether or not APCs expressed DLL4 and
was equivalent to control T cells stimulated by DLL4 APCs
(Figure 3A). These data are consistent with a previous report in
which Rbpj/ and WT T cells proliferated equivalently when
stimulated by anti-CD3+CD28. However, when APCs were
added as a source of NotchL, only the proliferation of WT cells
was enhanced (Tanigaki et al., 2004). The fact that Rbpj/
T cells were refractory to DLL4 also indicates that the effects
of DLL4 on priming were largely the result of canonical Notchy Important for CD4+ T Cell Activation In Vivo and In Vitro
ut 2.5 nM PCC, and analyzed for Notch1 and Notch2.
g [PCC] and analyzed for Notch1.
LL4 (heavy black line); unstained control overlaid for comparison (dotted line).
teins.
Dll4flox Itgax-cre (WT) or Itgax-cre+ (Dll4/) male mice that express H-Y Ag
ontrols. Bottom: each symbol represents one mouse, analyzed individually.
 CD11c+ splenocytes presenting 5 nM Dby peptide, in vitro. Mean ± SEM,
resenting 5 nM Dby peptide analyzed for CD69 induction and IL-2 secretion.
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Figure 2. An In Vitro System Accurately Recapitulates In Vivo Observations
(A) 5cc7 T cells stimulated overnight with 1 nM PCC presented by CD11c+ DCs or control or DLL4-P13.9 analyzed for CD69.
(B) 5cc7 T cells stimulated overnight with PCC presented by control or DLL4-P13.9 analyzed for CD69. Mean ± SEM fromR3 determinations for each dose of Ag;
control versus DLL4: 0.1 nM *p = 0.044, 1 nM *p% 0.0001, 10 nM *p% 0.0001, 100 nM *p% 0.0001, 1,000 nM *p% 0.0001.
(C) T cells cultured for 3 days with control or DLL4-P13.9 presenting PCC analyzed after a 24 hr pulse with 3H thymidine. Mean ± SEM fromR3 determinations for
each dose of PCC; control versus DLL4: 0.01 nM *p = 0.04, 0.03 nM *p = 0.0001, 0.10 nM *p% 0.005, 0.30 nM *p% 0.0001, 1 nM *p = 0.0002, 3 nM *p% 0.0001,
10 nM *p% 0.0001, 30 nM *p% 0.0001, 100 nM *p% 0.0005, 300 nM *p% 0.0001, 1,000 nM *p% 0.0001.
(D) 5cc7 T cells were stimulated as in (A). Live CD4+ cells were analyzed for increased biomass. n > 10.
(E) 5cc7 T cells cultured for 3 days with control or DLL4-P13.9 and 1 nM PCC harvested and analyzed for CFSE dilution. n = 2.
(F) 5cc7 T cells counted after 3 days in culture with control or DLL4-P13.9 and PCC.
Mean ± SEM ofR4 determinations; control versus DLL4: 1 nM *p% 0.02, 10 nM *p% 0.03, 1,000 nM n.s.
See also Figure S2.
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Figure 3. DLL4 Augments Metabolic Parameters in Activated CD4+ T Cells
(A) RbpjfloxCd4-cre (WT) or -cre+ (Rbpj/) 5cc7 T cells stimulated overnight with 4 nM PCC presented by control or DLL4-P13.9 and analyzed for activation
markers.
(B and C)WT 5cc7 T cells stimulated with 3 nMPCC presented by control or DLL4-P13.9 analyzed for induction of activationmarkers, and uptake of fluorescently
labeled analogs of transferrin (B) or glucose (C). Data are representative ofR3 determinations. Data frommultiple experiments withWT T cells were compiled and
subjected to statistical analysis; see Figure 5.signaling, rather than increased adhesion or noncanonical Notch
signaling.
DLL4 Increases IL-2
We used capture assays to quantify the frequency of cells
secreting IL-2 in response to pMHC presented by our APC lines
(Figures 4A and 4B). More T cells secreted IL-2 in response to
DLL4+ than to control APCs, consistent with what we observed
when using WT and Dll4/ DCs to stimulate Marilyn T cells.As was the case with CD69 induction, IL-2 expression was
RBPJ dependent, peptide dependent, and dose responsive,
and the frequency of IL-2+ cells reached a plateau at a lower con-
centration of Ag when T cells were stimulated in the presence of
DLL4. The data from IL-2 capture assays were corroborated by
measuring total IL-2 in culture supernatants (Figure 4C). These
data show that DLL4 reduced the threshold of Ag necessary to
induce IL-2 across a range of Ag doses, but was best appreci-
ated when pMHC was limiting.Immunity 42, 80–94, January 20, 2015 ª2015 Elsevier Inc. 85
Figure 4. DLL4 on APCs Increases IL-2 Production
(A) 5cc7 T cells cultured overnight with control or DLL4-P13.9 and PCC and analyzed for CD69 and IL-2 secretion.
(B) Rbpjflox Cd4-Cre or - Cre+ 5cc7 T cells stimulated overnight with 2.5 nM PCC presented by control or DLL4-P13.9 analyzed for IL-2 secretion. Mean ± SEM
ofR4 determinations. Control *p% 0.03, Rbpj/ n.s.
(C) Concentration of IL-2 in 48 hr supernatants of 5cc7 T cells cultured with control or DLL4-P13.9. Mean ± SEM ofR3 determinations; 1 nM *p% 0.05; 10 nM
*p% 0.04; 1,000 nM n.s.
(D) 5cc7 Il2-GFP T cells cultured overnight with control or DLL4-P13.9 and 1 nMPCCanalyzed for CD69 andGFP.Mean ± SEMofR5 determinations, *p% 0.002.
(E) 5cc7 Il2-GFP T cells cultured for up to 4 days with control or DLL4-P13.9 and 2.5 nM PCC analyzed for GFP. Open symbols on day 1 are 0 nM PCC.
Mean ± SEM, day 1 *p% 0.0001, day 2 *p% 0.03, days 3, 4 n.s.
See also Figure S3.To determine whether Notch signaling influenced the kinetics
of an IL-2 response, Il2 gene expression in T cells of mice with an
Il2-green fluorescent protein reporter (Il2-GFP) was analyzed
(Figures 4D, 4E, and S3). In the absence of DLL4, not only was
the magnitude of the response diminished, but the peak of the
Il2-GFP response was delayed. Collectively, the data demon-
strate that Notch signaling accelerates the kinetics of the
response, increases the magnitude of the response by
increasing the frequency of IL-2 expressing cells, and, ultimately,
produces more IL-2.86 Immunity 42, 80–94, January 20, 2015 ª2015 Elsevier Inc.Notch Works in Concert with CD28-Mediated
Co-Stimulation
The co-stimulatory effects of DLL4 on primary T cell responses
were reminiscent of the effects typically associated with the
CD28 ligands, CD80 and CD86, also known as ‘‘signal 2’’ (Frau-
wirth et al., 2002; Jacobs et al., 2008). To isolate the individual
consequences of Notch and CD28 signaling, additional APC
lines were created. Fibroblasts expressing equivalent amounts
of CD54 and MHCII, without CD80, were transfected with
DLL4 or control vector and used to present peptide to T cells
in side-by-side comparisons with CD80-bearing APCs (Fig-
ure S4). As established in Figures 2, 3, and 4, APCs that ex-
pressed both CD80 and DLL4 were potent stimulators of naive
CD4+ T cells. As expected, CD80+ APCs were more efficient
than CD80 APCs in their ability to stimulate nutrient transporter
expression and function (Figures 5A, 5B, and S4), IL-2Ra expres-
sion (Figures 5A and S4), blastogenesis (Figures 5C and S4),
and Il2-GFP expression (Figure 5D). Surprisingly, APCs that ex-
pressed only DLL4, and not CD80, were poor inducers of T cell
activation. Similar results were obtained when CD80:CD28 inter-
actions were abrogated by addition of blocking anti-CD80 anti-
body (mAb) or CTLA4-Fc (Figure 5E). Thus, the co-stimulatory
effects of DLL4 were predicated on the presence of pMHC and
CD80, suggesting that the major effect of Notch signaling was
to potentiate Ag-specific signaling downstream of CD28.
Notch Augments the PI3K Pathway Downstream
of CD80:CD28
One signaling cascade activated downstream of CD28 involves
PI3K and mTOR (Riha and Rudd, 2010). We found that T cells
primed in the absence of NotchL showed evidence of decreased
PI3K activity, such as decreased biomass and less of the PI3K-
regulated proteins CD71 and Glut1. To formally demonstrate
that PI3K activity was linked to Notch signaling, we confirmed
that phosphorylation of downstream targets of mTOR were
decreased when T cells were stimulated in the absence of a
NotchL. The frequency of cells with activated ribosomal protein
S6 (pS6), phospho-inactivated 4 elongation factor binding pro-
tein 1 (p4EBP1), and phospho-inactivated glycogen synthase
kinase-3 beta (pGSK3b) was diminished when APCs lacked
DLL4 (Figures 6A, 6B, and S5), indicating that Notch signaling
potentiates signaling downstream of PI3K. The increased phos-
phorylation of proteins that occurred when DLL4 was present
was dependent on CD28, PI3K, and pyruvate dehydrogenase
kinase-1 (PDK1), as shown by the fact that the co-stimulatory ef-
fects of DLL4 were negated by treatment with pharmacological
inhibitors of these kinases or when CD80:CD28 interactions
were sterically hindered (Figures 6B, S5, and data not shown).
Sustained signaling via TCR+CD28 leads to the synthesis and
nuclear translocation of the transcription factor NFATc1 (Nurieva
et al., 2007). Phospho-inactivation of GSK3b is a prerequisite
for IL-2 expression because it prolongs the nuclear retention of
transcription factors, including NFAT (Ohteki et al., 2000). We
examined the induction and cellular localization of NFATc1 in
individual T cells (Figures 6C and S6). NFATc1 was difficult
to detect in resting (CD69CD71) T cells but was highly ex-
pressed in activated (CD69+CD71+) cells. NFATc1 in activated
cells was largely confined to the nucleus, regardless of whether
cells became activated in the presence or absence of DLL4.
However, the frequency of cells that became NFATc1bright was
significantly higher in the presence of DLL4, consistent with the
observed increases in the frequency of cells with pGSK3b and
secreting IL-2.
We considered two explanations for how DLL4 on APCs could
lead to increased PI3K activity in T cells. One possibility was that
Notch signaling potentiates PI3K signaling downstreamof CD28.
A second possibility was that increased PI3K signaling was
secondary to the increased IL-2 because IL-2R signaling also
activates PI3K (Liao et al., 2013). To determine whether DLL4increased PI3K signaling upstream of IL-2 secretion and/or
downstream of IL-2R signaling, we used control or DLL4-APCs
to stimulate IL-2-deficient (Il2/) T cells. The magnitude of the
DLL4-associated increases in biomass, CD69, CD71, CD98,
Glut1, pS6, and p4EBP1 were the same in the presence and
absence of IL-2 (Figures 6D, S5, and data not shown). These
findings indicated that during the priming phase, DLL4-mediated
increases in PI3K signaling were a consequence of Notch re-
enforcing signals downstream of CD28 and occurred indepen-
dently of DLL4’s ability to increase the availability of IL-2.
DLL4 on DCs Is Essential for an Effective
Anti-Tumor Response
Our data suggest that Notch signals can enhance CD4+ T cell
priming, which could critically alter the course of an immune
response. To test this hypothesis, we used a model in which
eradication of a tumor is dependent on cross-presentation of
tumor Ag to CD4+ T cells by host MHCII+ APCs (Perez-Diez
et al., 2007). In the absence of T cells, tumor cells injected into
WT or Dll4/ recipients grew at a similar rate and resulted in
100% mortality in less than 5 weeks (Figure 7A). Adoptively
transferred Marilyn T cells responded to Ag derived from the
tumor cells and constrained tumor growth in WT mice. The
anti-tumor effect of Marilyn T cells was impaired in Dll4/
mice. Tumors grew larger, as compared to WT littermates, and
this led to a significant increase in mortality.
The inability of T cells to control tumor growth in the absence
of DLL4+ APCs could not be attributed to a failure of T cells to
survive in Dll4/ mice, because CD4+ T cells were present
in the tumor draining lymph node (LN) and the tumor itself (Fig-
ure 7B and data not shown). This suggested to us that the
impaired ability of mice with Dll4/ DCs to eradicate tumors
was due to qualitative differences in T cells stimulated in the
presence or absence of DLL4 on APCs. T cells isolated from
Dll4/ mice tended to have less CD98 than T cells isolated
fromWTmice (Figure 7C), consistent with diminished PI3K activ-
ity in the absence of DLL4-induced Notch signaling. This
occurred in spite of the fact that Dll4/ mice tended to have
larger tumors, and thus increased Ag burden. This phenotype
was similar to the diminution in CD98 that was observed on
T cells transferred into Dll4/ or WT male mice (Figure 1D).
Thus, DLL4 on APCs was essential for efficient activation and
function of CD4+ T cells during an anti-tumor response.
DISCUSSION
The data presented here provide compelling evidence that inter-
actions between DLL4 on APCs and Notch on naive T cells are a
critical factor in determining themagnitude and quality of primary
immune responses. We have shown that DLL4 improved CD4+
T cell priming in vivo and in vitro. On a population level, the
frequency of CD4+ T cells that became activated and secreted
IL-2 in response to a given concentration of Ag was greater
when T cells were primed in the presence of DLL4. On a per-
cell basis, Notch signaling was associated with elevated expres-
sion of nutrient receptors, improved nutrient uptake, greater
biomass, and increased proliferation. DLL4-mediated enhance-
ment of T cell activation was pMHC dependent, Ag dose
responsive, and predicated on the co-engagement of otherImmunity 42, 80–94, January 20, 2015 ª2015 Elsevier Inc. 87
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co-stimulatory molecules expressed on APCs. Collectively,
these data indicate that DLL4-induced Notch signaling is a
mechanism by which APCs can fine tune the Ag sensitivity of
CD4+ T cell responses.
DLL4 facilitated T cell priming as measured by numerous indi-
cators of T cell activation, including CD69, CD71, CD98, Glut1,
FSC, and proliferation. When a single parameter was followed
over a series of peptide concentrations, it was quite clear that
Notch facilitated priming across a broad range of Ag doses.
For certain parameters, the effects of DLL4 were difficult to
appreciate if T cells received a strong stimulus because once
a parameter reached its plateau, the effects of Notch were
obscured. For example, Marilyn T cells transferred into recipi-
ents that ubiquitously express H-Y Ag became uniformly
CD69+ in WT or Dll4/ mice. However, when Ag was titrated
down, it became clear that fewer T cells became CD69+ if stim-
ulated in the absence of a NotchL.
The dose-dependent nature of Notch effects might be one
reason that the role of Notch in T cell priming has not been widely
appreciated. For example, Adler et al. (2003) concluded that
Notch signaling had no effect on T cell activation, based on
CD69 induction. However, only one dose of Ag was assayed,
and that dose of peptide was high enough to induce nearly
100% of cells to become CD69+. Similarly, two groups reported
that Notch signaling does not enhance T cell proliferation
(Ong et al., 2008; Helbig et al., 2012). In both cases a very strong
TCR stimulus was provided, and therefore a likely explanation
for their results is that proliferation had already reached its
plateau. These observations are analogous to the finding that
with high doses of TCR stimulation, anti-CD28 co-stimulation
cannot further increase Glut1 expression or the frequency of
dividing cells (Wells et al., 1997; Teh and Teh, 1997; Jacobs
et al., 2008).
Most notably, our data illustrate that the source of NotchL is
critically important in vivo. DLL4 is expressed bymany cell types.
However, deletion of DLL4 specifically on CD11c+ APCs
impaired CD4+ T-cell-dependent immune responses to endoge-
nously expressed protein or exogenously added peptide Ag. It
will be interesting to see how targeted deletion of NotchL on
different subsets of APCs, such as CD103+ DCs in the mucosa
or B220+ plasmacytoid DCs, impacts T cell responses including
infection and tolerance.
Nutrient transporters are low on resting T cells and are among
the earliest proteins upregulated in response to PI3K signaling
downstream of TCR+CD28 (Cotner et al., 1983; Edinger, 2007;
Jacobs et al., 2008). We found that phosphorylation of proteins
downstreamof PI3Kwas enhancedwhen T cells were stimulated
by DLL4+ APCs, and this was associated with increased induc-Figure 5. DLL4:Notch Work in Concert with CD80:CD28 Signaling
(A) 5cc7 T cells cultured with 1 nM PCC and control or DLL4-P13.9, with or witho
CD80+ control versus DLL4: CD69 *p% 0.0001, CD98 *p% 0.02, CD71 *p% 0.
(B) 5cc7 T cells were stimulated as in (A) and the amount of fluorescently labele
terminations. Tf: CD80+ control versus DLL4 0.01 nM *p% 0.008, CD80 contro
control versus DLL4 n.s. p = 0.76.
(C) T cells cultured overnight with control or DLL4-P13.9, with or without CD80,
frequency of blasting cells (FSChi) mean ± SEM fromR3 experiments at each dose
(D) 5cc7 Il2-GFP T cells, cultured with 10 nM PCC and control or DLL4-P13.9, w
(E) 5cc7 T cells were stimulated as in (D) and where indicated aCD80 mAb or CT
See also Figure S4.tion of nutrient receptors. Conversely, when T cells were acti-
vated in the absence of DLL4, we found that induction of
CD71, endocytosis of Tf:iron complexes, IL-2 secretion, and
proliferation were diminished. Because proliferation and cyto-
kine secretion are constrained in cells that cannot take up
adequate iron (Bayer et al., 1998), our data might explain why
mice with iron deficiency are less susceptible to Notch1-induced
leukemia (Khwaja et al., 2010).
The effects of Notch signaling that we describe during the
priming phase of CD4+ T cell responses bear similarities to the
cooperative relationship between preTCR and Notch during
b-selection in thymocytes. During both processes, signaling
through Ag receptor and Notch allows selective expansion of
cells by upregulating nutrient receptors in a PI3K- and PDK1-
dependent manner (Cotner et al., 1983; Kelly et al., 2007; Brekel-
mans et al., 1994b). In mature CD4+ T cells, we found that the
trophic effects of DLL4 boosted metabolism only in T cells re-
sponding to pMHC+CD80. With a diverse TCR repertoire, this
mechanism would allow Ag-specific T cells to preferentially
expand. It might also help to maintain peripheral tolerance,
because NotchL are ubiquitously expressed and might other-
wise facilitate expansion of T cells that see Ag in the absence
of signal 2.
We observed that Rbpj/ T cells were refractory to the pres-
ence of DLL4 on APCs, suggesting that DLL4-induced changes
during the priming phase are the consequence of canonical
Notch signaling. For example, DLL4 did not increase nutrient
transporter expression or FSCs of Rbpj/ T cells. Complemen-
tary data show that inhibition of Notch in T-ALL cells by domi-
nant-negative mastermind-like-1 or a g-secretase inhibitor
decreased cell size (Chan et al., 2007). The promoters of the
Notch-responsive genes that we monitored lack consensus
RBPJ binding sites, but the possibility that some of these genes
have RBPJ binding sites in distal enhancers cannot be excluded
(Wang et al., 2014). Nevertheless, we favor the interpretation that
the Notch-responsive proteins that we measured were indirectly
regulated by Notch signaling.
By regulating the activity of GSK3b, Notch signaling can influ-
ence the activity of >40 proteins that are targets of GSK3b-me-
diated regulation including NFAT, AP-1, and NF-kB transcription
factors (McCubrey et al., 2014; Pollizzi and Powell, 2014). The Il2
promoter contains binding sites for numerous transcription fac-
tors, all of which must be bound for optimal transcription of Il2
mRNA (Rothenberg andWard, 1996). Inactivation of GSK3b pro-
longs the nuclear residency of transcription factors at the Il2 pro-
moter and increases Il2 gene expression (Ohteki et al., 2000).
Previous studies have shown that Notch signaling increases
the nuclear retention of NF-kB and the total amount of IL-2ut CD80, analyzed for activation markers. Mean ± SEM ofR3 determinations;
002, Glut1 *p% 0.001, CD25 *p% 0.001. CD80 control versus DLL4: n.s.
d Tf or glucose compared as in Figures 3B and 3C. Mean ± SEM of R3 de-
l versus DLL4 n.s. Glucose: CD80+ control versus DLL4 n.s. p = 0.17, CD80
and increasing doses of PCC, analyzed for increased biomass. Data are the
. Control versus DLL4: 1 nM *p% 0.001, 10 nM *p% 0.008, 100 nM *p% 0.002.
ith or without CD80 analyzed for GFP.
LA4-Fc was added. Data are representative ofR3 determinations.
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Figure 7. DLL4 on DC Is Essential for a
Protective CD4+ T-Cell-Dependent Anti-
Tumor Response
Tumor cells were injected in toCd3ε/Dll4floxItgax-
cre (WT) or -cre+ (Dll4/) animals and some mice
received Marilyn T cells 2 days later.
(A) Tumor volumes (top) plotted until the day that
the first mouse in the group was lost (bottom).
Data are representative of R2 experiments, each
with R3 mice per experimental group. Log-rank
(Mantel-Cox) tests of survival control versus Dll4/
*p% 0.004.
(B) Tumors analyzed for the presence of Marilyn
T cells (CD4+TCRVb6+).
(C) Tumor-infiltrating T cells analyzed for signs
of activation. Data are representative of R2 pairs
of mice.(Shin et al., 2006; Dongre et al., 2014). We have demonstrated
here that pGSK3b, NFATc1 induction and nuclear translocation,
Il2 gene expression, and IL-2 secretion are all increased when
T cells are primed in the presence of NotchL. Thus, Notch
signaling coordinately regulates the expression, activity, and
cellular localization of multiple proteins that control Il2 gene
expression.
Notch has been described as instructive for the differentiation
of Th1, Th2, Th17, follicular Th, and Treg cells (Amsen et al.,
2007; Minter et al., 2005; Samon et al., 2008; Mukherjee et al.,
2009; Auderset et al., 2013; Keerthivasan et al., 2011). Although
it is formally possible that Notch specifies commitment to all of
these lineages, our data offer a simpler explanation. Because
these CD4+ T cell effector cell lineages are each dependent on
IL-2 (Liao et al., 2013; MacIver et al., 2013), decreased IL-2 pro-
duction in the absence of Notch would explain most of the earlier
findings. We propose that Notch promotes the generation of
CD4+ T cell effector lineages not by specifying lineage choice
or inducing expression of master regulators, but by facilitating
T cell activation, metabolic reprogramming, and IL-2 secretion
during the first few hours after Ag encounter. This hypothesis
does not exclude the possibility that at later time points Notch
signaling reinforces or amplifies the expression of lineage-spe-
cific genes in fully differentiated T cells.
The findings presented here suggest that the therapeutic
potential of harnessing Notch is not limited to a particular
Th-cell-biased pathology, but will be broadly applicable. DLL4-Figure 6. DLL4:Notch Increase PI3K-Dependent Phosphorylation of Proteins Downstream of
(A and B) 5cc7 T cells cultured overnight with 2.5–5 nM PCC and CD80+ control or DLL4-P13.9 analyzed f
indicated, inhibitors were added.
(C) 5cc7 T cells cultured overnight with CD80+ control or DLL4-P13.9 presenting 3 nM PCC analyzed for i
shown are live, diploid, CD4+ cells. Numbers in the upper left corner of the bright field images are the uniq
(Amnis). Graphs are the mean ± SEM. Similarity between NFATc1 and DAPI control versus DLL4 n.s. Freque
(D) WT or Il2/ 5cc7 T cells cultured overnight with control or DLL4-P13.9 APCs and 2.5 nM PCC analyze
Data are representative ofR3 experiments. See also Figures S5 and S6.
Immunity 42, 80–blocking mAbs suppress disease in
models of multiple sclerosis, graft-
versus-host disease, and transplantation
(Takeichi et al., 2010; Tran et al., 2013; Ish-
ida et al., 2011). Based on our findings that
CD4+ T cell responseswere impaired in theabsence of DLL4 on APCs, we posit that the immune-suppres-
sive effects of DLL4 mAb in these models were due to less-effi-
cient T cell priming. Our results suggest that strategies targeting
DLL4 on CD11c+ cells (Kontermann, 2012) would offer powerful
remedies for autoimmune disease without the adverse effects of
systemic blockade of DLL4 (Pellegrinet et al., 2011; Yan et al.,
2010). Our observation that DLL4 confers a growth advantage
to Ag-specific T cells also suggests that DLL4-induced Notch
signaling could be used to optimize immunotherapy. Clinical tri-
als evaluating the efficacy of ex vivo expanded autologous
T cells to treat malignancies report that a major limitation is the
time required to grow enough T cells to transfer back into the pa-
tient (Weber et al., 2011). Our data suggest that DLL4 could facil-
itate expansion of tumor-specific T cells and decrease the time
required to generate sufficient T cells for immunotherapy.
In conclusion, we show that DLL4 is a mechanism by which
APCs can fine tune adaptive immune responses, by influencing
the sensitivity, magnitude, and quality of the initial CD4+ T cell
response. The findings presented here provide insight as to
how a generic signaling pathway like Notch can work in concert
with Ag- and APC-specific signals to enhance T cell priming. The
highly context-dependent nature of Notch signaling is ideal for
tailoring immune responses to specific situations. The outcome
of Notch signaling in T cells is likely to vary depending on the
identity of the APCs, co-engagement of other co-stimulatory or
inhibitory molecules, cytokine milieu, and other environmental
factors. Coupling in vivo observations with mechanistic dataCD80:CD28
or phosphorylation of the proteins indicated. Where
nduction of NFATc1, CD69, and CD71. The images
ue object identifier assigned to each cell by Inspire
ncy of NFATc1bright control versus DLL4 *p% 0.002.
d for signs of activation and PI3K signaling.
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acquired in willfully reductionist in vitro systems could provide
innovative approaches for manipulating Notch signaling to treat
autoimmunity, infection, and other pathologies.
EXPERIMENTAL PROCEDURES
Mice
Mice were maintained under specific-pathogen-free conditions. All experi-
ments were performed in compliance with NIAID Animal Care and Use
Committee (ACUC) protocols and regulations. A detailed list of mice is pro-
vided in the Supplemental Experimental Procedures.
Cell Isolation
Spleens, LNs, and tumors were harvested in M199 (Invitrogen) supplemented
with fetal calf serum (FCS) (Gemini Bio-Products), L-glutamine (Quality
Biological), and antibiotic-antimycotic (Invitrogen). Single-cell suspensions
were made by passing cells through 100 mm nylon mesh. Splenocytes were
enriched for MHCII+ or CD11c+ cells via magnetic beads and an AutoMACS
(Miltenyi). T cells were not previously activated. No exogenous adjuvants
were added.
Adoptive Transfers
0.5–2.5 3 106 Marilyn LN cells, which are specific for an H-Y-derived peptide
presented by MHCII I-Ab, were injected intravenously into T-cell-replete
H-2b male and female recipients. 3 days later, cells isolated from spleen and
LN were analyzed for the presence of donor cells.
Tumor Challenge
105 MB49 carcinoma cells (originally isolated from an H-2b male mouse) were
injected subcutaneously on the right flank of H-2b Cd3ε/ female recipients.
2 days after tumor challenge, 106 Marilyn T cells were injected intraperitone-
ally. Tumors were measured with calipers every other day, and tumor volumes
were calculated as length 3 width 3 heightO 2. Mice were euthanized when
they became distressed or if tumor volume exceeded 1,000 mm3.
Antibodies and Fluorescently Labeled Probes
A detailed list of antibodies and fluorescently labeled probes is provided in the
Supplemental Experimental Procedures.
Antigen-Presenting Cell Lines
L cells with constitutive expression of CD54 and MHCII I-Ek with (P13.9)
or without CD54 (EKAM) (Lucas and Germain, 2000) were provided by R.
Germain (NIAID, NIH). Cells were maintained in complete DMEM (cDMEM)
(DMEM [Invitrogen] supplemented with FCS, L-glutamine, sodium pyruvate
[Invitrogen], antibiotic-antimycotic, and gentamycin [Invitrogen]). MIGR1-
empty vector and MIGR1-mDLL4 constructs were nucleofected into P13.9
or EKAM cells with an Amaxa Nucleofector (Amaxa Biosystems). Flow cyto-
metric sorting was used to select stable clones with comparable retrovirus
integration (GFP), MHCII, CD54, and CD80. Surface expression of DLL4 was
confirmed by staining with anti-DLL4 antibody.
In Vitro Stimulation
T cells and APCs were incubated overnight at a ratio of 10:1 in complete RPMI
(cRPMI) (RPMI1640 [Invitrogen] supplemented with FCS, L-glutamine, sodium
pyruvate, non-essential amino acids (Invitrogen), antibiotic-antimycotic, and
2-ME [Invitrogen]). Dby and Pigeon cytochrome c peptides were purchased
from Anaspec. A pharmacological inhibitor of PI3K (Ly294002) was purchased
from Cell Signaling.
Flow Cytometry
For surface staining, cells were resuspended in HBSS+BSA+NaN3 (Quality
Biological) with properly diluted antibodies. For intracellular staining, cells
were fixed with 4% PFA in PBS (Ted Pella) for 30 min and then permeabilized
with 0.5% Triton X-100 (Sigma) in PBS with 0.1% IgG-free BSA (Jackson
Immunoresearch). IL-2 secretionwas detected with a cytokine secretion assay
(Miltenyi). Live cells were gated based on exclusion of 7AAD (eBioscience) or
Live Dead Fixable dyes (Invitrogen). Data collected on a FACS Calibur or92 Immunity 42, 80–94, January 20, 2015 ª2015 Elsevier Inc.FACS Canto II (BD) were analyzed in FlowJo (Treestar). For NFATc1 localiza-
tion, data were collected with an ImagestreamX Mark II imaging flow cytome-
ter (Amnis/EMD Millipore). Data were analyzed with IDEAS (Amnis/EMD
Millipore). Images were taken at 603 magnification.
Proliferation
For 3H incorporation, APCs were incubated for 2 hr with mitomycin C
(10 mg/ml; Calbiochem) in cDMEM and then rinsed with 13 PBS. T cells and
APCs were resuspended in cRPMI at a ratio of 10:1 with PCC peptide.
After 48 hr, culture supernatants were removed and replaced with cRPMI
supplemented with 1 mCi [3H] thymidine. After an additional 24 hr, cultures
were harvested and the amount of [3H]thymidine incorporated was determined
with a scintillation counter.
For CFSE dilution, T cells were incubated with 1 mM carboxy-fluorescein
diacetate succinimidyl ester (CFSE) (Invitrogen) in PBS+0.5% FCS, washed
with FCS, and then T cells and APCs were re-suspended in cRPMI at a ratio
of 10:1 with PCC peptide. After 3 days, cultures were harvested and the
amount of CFSE dilution was determined.
IL-2 ELISA
APCs were incubated for 2 hr with mitomycin C in cDMEM and rinsed with
13 PBS. T cells and APCs were incubated in cRPMI at a ratio of 10:1 with
PCC peptide. Supernatants were collected after 48 hr and analyzed by Quanti-
body Array (RayBiotech). The limit of detection for IL-2 was 30 pg/ml.
Statistics
Data are presented as the mean ± SEM. Two-tailed unpaired Student’s
t tests and log-rank (Mantel-Cox) tests of survival curves were performed
with Prism6 (GraphPad). A p value of %0.05 was considered significant and
marked with an asterisk (*); a p value >0.05 was considered non-significant
(n.s.). Similarity scores, calculated by IDEAS, are the log transformed Pear-
son’s Correlation Coefficient of pixel intensity for NFATc1 and DAPI.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2014.12.027.
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